Prostate Cancer Therapeutics Market @ http://www.researchmoz.us/prostate-cancer-therapeutics-market-to-2019-rising-prevalence-and-strong-uptake-of-recent-approvals-to-drive-robust-growth-to-2019-report.html The recent approval of a number of highly effective drugs, including Zytiga and Xtandi, has provided late-stage patients with a number of options and increased survival times by a number of months. These recent approvals are anticipated to generate strong revenues during the forecast following increasing uptake by physicians as the treatment algorithm shifts towards their first-line usage over Taxotere.

1. Prostate Cancer Therapeutics Market to 2019 - Rising Prevalence and Strong Uptake of Recent Approvals to
Drive Robust Growth to 2019
GBI Research has released the pharmaceutical report - “Prostate Cancer Therapeutics Market to 2019 Rising Prevalence and Strong Uptake of Recent Approvals to Drive Robust Growth to 2019”. The
recent approval of a number of highly effective drugs, including Zytiga and Xtandi, has provided late-stage
patients with a number of options and increased survival times by a number of months. These recent approvals
are anticipated to generate strong revenues during the forecast following increasing uptake by physicians as
the treatment algorithm shifts towards their first-line usage over Taxotere. Additionally, a very large late-stage
pipeline is anticipated to produce a number of new market entrants which are superior to existing products.
Overall, this is anticipated to drive rapid market growth from $4.1 billion in 2012 to $8.0 billion by 2019 at a
CAGR of 10.1%.
Scope
A brief introduction to prostate cancer, including the disease’s pathogenesis, risk factors, diagnosis,
staging and treatment algorithms for each stage. In-depth analysis of drugs available for the treatment of
prostate cancer, including analyses of their safety, efficacy, treatment patterns and strengths/weaknesses.
Includes a heat map comparing the drugs in terms of safety and efficacy. Comprehensive review of the
pipeline for prostate cancer therapies, including individual analysis of a number of late-stage pipeline drugs
that are likely to enter the market in the forecast period. The pipeline is analyzed on the basis of phase
distribution, molecule types and molecular targets, program type. Additional in-depth analysis of pipeline drug
clinical trials by phase, molecule type, trial size, trial duration and program failure rate analyses for each
molecule type and mechanism of action. Multi-scenario forecast data of the market to 2019, taking into
account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs
and the changes in disease epidemiology across the key developed markets including the US, Japan, Germany,
the UK, France, Italy and Spain. Discussion of the drivers and barriers for market growth. Discussion of the
licensing and co-development deals landscape in prostate cancer, Includes an analysis of licensing deals by
stage of development, molecule type and mechanism of action. Also includes an analysis of both licensing and
co-development deals by year and value and network maps of licensing and co-development deals.
Reasons to Buy
Understand the different levels of prostate cancer therapies, from early-stage prostate cacner to metastatic
and castrate-resistant prostate cancer. Understand the vast scope and diversity of the pipeline, including which
molecule types and mechanisms of action are prominent. Observe the trends in clinical trial duration and size
amongst clinical Phases, between molecule types and mechanisms of action, and use the clinical trial failure
rate analysis to assess the risk profiles of current and/or future developmental programs for prostate cancer
therapeutics. Assess the potential clinical and commercial impact of current late-stage pipeline molecules on
the prostate cancer therapeutics market.
table Of Content
Prostate Cancer Therapeutics Market to 2019 - Rising Prevalence and Strong Uptake of Recent Approvals to Drive Robust Growth to 2019

2. 1 Table Of Contents
1.1 List Of Tables
1.2 List Of Figures
2 Executive Summary
2.1 Strong Growth Expected In Prostate Cancer Market
2.2 Novel Therapies Offer New Hope For Prostate Cancer Treatment
2.3 Large Pipeline, But High Failure Rate
3 Introduction
3.1 Pathophysiology And Etiology
3.2 Epidemiology
3.3 Disease Progression
3.4 Treatment
4 Marketed Products
4.1 Hormonal Therapies
4.1.1 Zoladex (goserelin) – Astrazeneca
4.1.2 Lupron Depot (leuprolide Acetate) – Abbvie
4.1.3 Triptorelin
4.1.4 Firmagon (degarelix) – Ferring
4.1.5 Casodex (bicalutamide)
4.1.6 Summary
4.2 Chemotherapy Agents
4.2.1 Taxotere (docetaxel) – Sanofi
4.2.2 Jevtana (cabazitaxel) – Sanofi
4.3 Therapeutic Vaccines
4.3.1 Provenge (sipuleucel-t) – Dendreon
4.4 Targeted Therapies (second Generation Anti-androgens)
4.4.1 Zytiga (abiraterone Acetate) – Janssen
4.4.2 Xtandi (enzalutamide) – Astellas/medivation
4.5 Bone Metastasis Treatments
4.5.1 Xofigo (radium 223) – Bayer/algeta
4.5.2 Xgeva (denosumab) – Amgen
4.5.3 Zometa (zoledronic Acid) – Novartis
4.6 Heat Map For Marketed Products
Prostate Cancer Therapeutics Market to 2019 - Rising Prevalence and Strong Uptake of Recent Approvals to Drive Robust Growth to 2019

3. 5 Prostate Cancer Developmental Pipeline
5.1 Overall Pipeline
5.2 Mechanisms Of Action
5.3 Clinical Trials
5.3.1 Attrition Rate
5.3.2 Enrollment
5.3.3 Duration
5.4 Key Late-stage Pipeline Molecules
5.4.1 Cometriq (cabozantinib) – Exelixis
5.4.2 Ogx-011 (custirsen Sodium) – Teva
5.4.3 Tak-700 (orteronel) – Takeda
5.4.4 Prostatak (advtk+ Valcyclovir) – Advantagene
5.4.5 Prostvac – Bavarian Nordic
5.4.6 Tasquinimod – Active Biotech
5.4.7 Yervoy (ipilimumab) – Bristol-myers Squibb
5.4.8 Arn-509 – Aragon Pharmaceuticals, Johnson And Jonhson
6 Market Forecast To 2019
6.1 Global
6.1.1 Treatment Usage Patterns
6.1.2 Market Size
6.2 North America
6.2.1 Us
6.2.2 Canada
6.3 Five European Markets
6.3.1 Treatment Usage Patterns
6.3.2 Annual Cost Of Therapy
6.3.3 Market Size
6.4 Japan
6.4.1 Treatment Usage Patterns
6.4.2 Market Size
7 Prostate Cancer Therapeutics: Drivers And Barriers
7.1 Drivers
7.1.1 Major Unmet Treatment Needs Of Late Stage Prostate Cancer Patients
7.1.2 Increasing Disease Population
7.1.3 New Drugs Entering The Market
7.1.4 Rapid And Robust Uptake Of Recently Approved High-cost Therapies
7.1.5 Rapid Inflation Rate For Specialty Pharmaceutical Products In The Us
7.1.6 Market Capture Of Previously Untreated Patient Segments
7.2 Barriers
Prostate Cancer Therapeutics Market to 2019 - Rising Prevalence and Strong Uptake of Recent Approvals to Drive Robust Growth to 2019

4. 7.2.1 Uncertain Treatment Algorithm
7.2.2 Uptake Limited By High Prices For New Products
7.2.3 Patent Expiry Of Taxotere
7.2.4 Intensifying Competition Acting As A Barrier To Market Capture
8 Licensing And Co-development Deals Analysis
8.1 Licensing Deals
8.1.1 Algeta Enters Into Licensing Agreement With Bayer Schering For Xofigo
8.1.2 Sanofi-aventis Enters Into A Licensing Agreement With Oxford Biomedica
8.1.3 Novacea Enters Into Licensing Agreement With Schering-plough For Asentar
8.1.4 Teva Pharma Enters Into A Licensing Agreement With Oncogenex Pharma For Ogx-011
8.1.5 Hoffman La Roche Enters Into A Licensing Agreement With Inovio Pharmaceuticals For Prostate
Cancer And Hepatitis B Immunotherapy Products
8.1.6 Colby Pharmaceutical Company Enters Into A Licensing Agreement With Mannkind For Cancer
Immunotherapy Products
8.1.7 Ipsen Enters Into A Licensing Agreement With Gtx
8.1.8 Protox Therapeutics Enters Into A Licensing Agreement With Kissei Pharma
8.1.9 Aeterna Zentaris Enters Into License And Collaboration Agreement With Nippon Kayaku For Ozarelix
8.1.10 Orion Corporation Enters Into Agreement With Indevus Pharmaceuticals
8.2 Co-development Deals
8.2.1 Medivation Enters Into Co-development Agreement With Astellas Pharma
8.2.2 Takeda Pharma Enters Into An Agreement With Cell Genesys
8.2.3 Active Biotech Enters Into Co-development Agreement With Ipsen
9 Appendix
9.1 Market Definitions
9.2 Abbreviations
9.3 Sources
9.4 Sources For Marketed Products Heat Map
9.5 Scientific Support
9.6 Research Methodology
9.6.1 Coverage
9.6.2 Secondary Research
9.6.3 Therapeutic Landscape
9.6.4 Epidemiology-based Forecasting
9.6.5 Market Size By Geography
9.6.6 Geographical Landscape
9.6.7 Pipeline Analysis
9.6.8 Competitive Landscape
9.6.9 Expert Panel Validation
9.7 All Publicly Announced Pipeline Products, By Phase
Prostate Cancer Therapeutics Market to 2019 - Rising Prevalence and Strong Uptake of Recent Approvals to Drive Robust Growth to 2019

5. 9.7.1 Discovery
9.7.2 Preclinical/ind-filed
9.7.3 Phase I
9.7.4 Phase Ii
9.7.5 Phase Iii/pre-registration
9.7.6 Undisclosed Stage Of Development
9.8 Tabular Forecast Data
9.8.1 Global
9.8.2 Us
9.8.3 Uk
9.8.4 France
9.8.5 Germany
9.8.6 Italy
9.8.7 Spain
9.8.8 Japan
9.8.9 Canada
9.9 Disclaimer
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research
reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our
huge collection of market research reports. We provide our services to all sizes of organizations and across all
industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as
publishers and will assist you in making an informed decision by giving you unbiased and deep insights on
which reports will satisfy your needs at the best price.
Contact:
M/s Sheela,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
Prostate Cancer Therapeutics Market to 2019 - Rising Prevalence and Strong Uptake of Recent Approvals to Drive Robust Growth to 2019